Medtronic Plc

Medtronic Plc, a key player in the Pharmaceuticals & Biotechnology sector, has seen its stock price slightly decrease to $87.21. Over the past year, it has fluctuated between $79.93 and $106.33. The company has faced challenges, with a year-to-date return of -9.21%, underperforming the S&P 500.

Medtronic Plc has recently encountered a technical event known as a Death Cross, indicating a potential shift in market sentiment. Current indicators suggest a bearish outlook, with underperformance relative to the S&P 500 over various time frames, raising concerns among investors about the stock's future trajectory.

Medtronic Plc, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a stock decline and underperformed compared to the S&P 500 over the past year. Technical indicators present a mixed outlook, emphasizing the need for careful analysis of the company's performance and strategic initiatives amid current market challenges.

Medtronic Plc, a key player in the Pharmaceuticals & Biotechnology sector, has seen its stock price decline recently, reflecting ongoing challenges. Over the past year, the company has underperformed compared to the S&P 500, with mixed technical indicators suggesting a period of consolidation and volatility in its stock performance.

Medtronic Plc has reported a challenging quarter in January 2026, with declines in key financial metrics. Despite achieving a record dividend per share and a decrease in raw material costs, concerns arise from low return on capital employed and cash reserves. The company's stock performance has been mixed compared to the S&P 500.

Medtronic Plc achieved a new 52-week high of USD 103.70 on November 24, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a notable increase over the past year, with solid financial metrics including a P/E ratio of 21.00 and a dividend yield of 3.08%.

Medtronic Plc has reported strong financial results for the quarter ending July 2025, showcasing an operating cash flow of USD 7,146 million and a return on capital employed of 9.72%. The company also achieved a dividend per share of USD 5.57 and a high inventory turnover ratio of 2.43 times, despite facing challenges with a high debt-equity ratio of 42.78%.

Medtronic Plc achieved a new 52-week high of USD 102.59 on November 19, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 20.69% increase over the past year, with a market capitalization of USD 119,277 million and a dividend yield of 3.08%.

Medtronic Plc's stock saw significant gains on November 18, 2025, reaching an intraday high. The company has outperformed the S&P 500 over the past week and month, with strong year-to-date returns. Key financial metrics highlight a solid operational foundation and stable investment environment, despite recent underperformance.

Medtronic Plc, a key player in the Pharmaceuticals & Biotechnology sector, has seen its stock price slightly decrease to $94.13. Over the past year, it reached a high of $99.37 and a low of $79.29. The company's performance has varied, with a 3.45% annual return, but it outperformed the S&P 500 year-to-date.

Medtronic Plc achieved a new 52-week high of USD 99.37 on October 7, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has gained 18.27% over the past year, with a market capitalization of USD 119,277 million and a dividend yield of 3.08%.

Medtronic Plc achieved a new 52-week high of USD 98.65 on October 6, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has gained 18.39% over the past year, with a solid financial profile characterized by a favorable debt-to-equity ratio and attractive dividend yield.

Medtronic Plc reached a new 52-week high of USD 97.94 on October 3, 2025, reflecting strong performance over the past year. With a market capitalization of USD 119,277 million, a P/E ratio of 21.00, and a dividend yield of 3.08%, the company demonstrates solid financial health and competitive valuation.